Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Sarilumab (Kevzara) and TOCILIZUMAB (Tofidence) — clinical data, side effects, and patient experiences.
Kevzara · IL-6 Receptor Inhibitor
How it works
Monoclonal antibody that binds IL-6 receptor, blocking IL-6-mediated inflammatory signalling.
Approved for
Tofidence, Actemra · IL-6 Receptor Inhibitor
How it works
12.1 Mechanism of Action Tocilizumab products bind to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and have been shown to inhibit IL-6-mediated signaling thr...
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for Sarilumab vs TOCILIZUMAB.
Both Sarilumab and TOCILIZUMAB belong to the IL-6 Receptor Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. Sarilumab is administered via Subcutaneous, whereas TOCILIZUMAB uses Intravenous. Route of administration can affect onset of action and patient adherence.
Sarilumab carries 3 FDA warnings. TOCILIZUMAB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.